• Immatics posted Q2 net loss of USD 71.2 million, narrowing from USD 80.1 million a year earlier.
• Revenue rose 92.59% to USD 10.4 million, due to higher collaboration activity and cost share versus plan.
• R&D expense climbed 38.33% to USD 71.1 million, driven by advancing clinical trials, particularly the SUPRAME study.
• Cash and financial assets fell to USD 448.2 million at June 30 from USD 534.7 million at Dec. 31; cash reach projected into 2028.
• SUPRAME enrollment remains on track for required randomizations by year-end; final PFS topline expected in H1 2027, BLA filing planned in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180700OMX_____CNEWS_EN_GNW1001258133_en) on August 18, 2026, and is solely responsible for the information contained therein.